{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T17:17:58Z","timestamp":1747156678113,"version":"3.40.5"},"reference-count":18,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.bulcan.2018.06.009","type":"journal-article","created":{"date-parts":[[2018,7,18]],"date-time":"2018-07-18T10:50:24Z","timestamp":1531911024000},"page":"739-741","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Strat\u00e9gies de maintenance dans les cancers du pancr\u00e9as avanc\u00e9s\u00a0: rationnel et enjeux"],"prefix":"10.1016","volume":"105","author":[{"given":"Anthony","family":"Turpin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hortense","family":"Chevalier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7037-7477","authenticated-orcid":false,"given":"Cindy","family":"Neuzillet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9\u201310","key":"10.1016\/j.bulcan.2018.06.009_bib0095","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1080\/0284186X.2016.1197419","article-title":"More deaths from pancreatic cancer than breast cancer in the EU by 2017","volume":"55","author":"Ferlay","year":"2016","journal-title":"Acta Oncol Stockh Swed"},{"issue":"11","key":"10.1016\/j.bulcan.2018.06.009_bib0100","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1158\/0008-5472.CAN-14-0155","article-title":"Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States","volume":"74","author":"Rahib","year":"2014","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.bulcan.2018.06.009_bib0105","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.bulcan.2017.11.004","article-title":"[Epidemiology of pancreatic cancer]","volume":"105","author":"Drouillard","year":"2018","journal-title":"Bull Cancer"},{"key":"10.1016\/j.bulcan.2018.06.009_bib0110","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.pharmthera.2015.08.006","article-title":"State of the art and future directions of pancreatic ductal adenocarcinoma therapy","volume":"155","author":"Neuzillet","year":"2015","journal-title":"Pharmacol Ther"},{"issue":"10073","key":"10.1016\/j.bulcan.2018.06.009_bib0115","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S0140-6736(16)32409-6","article-title":"Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3\u00a0trial","volume":"389","author":"Neoptolemos","year":"2017","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.bulcan.2018.06.009_bib0120","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.18_suppl.LBA4001","article-title":"Unicancer GI PRODIGE 24\/CCTG PA.6\u00a0trial: a multicenter international randomized phase III trial of adjuvant mFOLFIRINOX versus gemcitabine (gem) in patients with resected pancreatic ductal adenocarcinomas","volume":"36","author":"Conroy","year":"2018","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/j.bulcan.2018.06.009_bib0125","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.bulcan.2018.06.009_bib0130","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2018.06.009_bib0135","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.pharmthera.2017.02.028","article-title":"Unravelling the pharmacologic opportunities and future directions for targeted therapies in gastro-intestinal cancers. Part 1: GI carcinomas","volume":"174","author":"Neuzillet","year":"2017","journal-title":"Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.bulcan.2018.06.009_bib0140","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.bulcan.2017.12.010","article-title":"[Metastatic colorectal cancer: to stop or not to stop?]","volume":"105","author":"Artru","year":"2018","journal-title":"Bull Cancer"},{"issue":"3","key":"10.1016\/j.bulcan.2018.06.009_bib0145","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1200\/JCO.2005.03.0106","article-title":"OPTIMOX1: a randomized study of FOLFOX4\u00a0or FOLFOX7\u00a0with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer\u2014A GERCOR study","volume":"24","author":"Tournigand","year":"2006","journal-title":"J Clin Oncol"},{"issue":"34","key":"10.1016\/j.bulcan.2018.06.009_bib0150","doi-asserted-by":"crossref","first-page":"5727","DOI":"10.1200\/JCO.2009.23.4344","article-title":"Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2\u00a0study","volume":"27","author":"Chibaudel","year":"2009","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.bulcan.2018.06.009_bib0155","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1159\/000444854","article-title":"Effectiveness and tolerability of maintenance capecitabine administrated to patients with metastatic pancreatic cancer treated with first-line FOLFIRINOX","volume":"90","author":"Reure","year":"2016","journal-title":"Oncology"},{"key":"10.1016\/j.bulcan.2018.06.009_bib0160","doi-asserted-by":"crossref","first-page":"41549","DOI":"10.1038\/srep41549","article-title":"Feasibility of alternating induction and maintenance chemotherapy in pancreatic cancer","volume":"7","author":"Hann","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.bulcan.2018.06.009_bib0165","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.4000","article-title":"FOLFIRINOX until progression, FOLFIRINOX with maintenance treatment, or sequential treatment with gemcitabine and FOLFIRI.3\u00a0for first-line treatment of metastatic pancreatic cancer: a randomized phase II trial (PRODIGE 35-PANOPTIMOX)","volume":"36","author":"Dahan","year":"2018","journal-title":"J Clin Oncol"},{"issue":"18","key":"10.1016\/j.bulcan.2018.06.009_bib0170","first-page":"3116","article-title":"Fixed-dose rate gemcitabine alone or alternating with FOLFIRI.3 (irinotecan, leucovorin and fluorouracil) in the first-line treatment of patients with metastatic pancreatic adenocarcinoma: an AGEO randomised phase II study (FIRGEM)","volume":"50","author":"Trouilloud","year":"2014","journal-title":"Eur J Cancer Oxf Engl 1990"},{"key":"10.1016\/j.bulcan.2018.06.009_bib0175","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.4107","article-title":"Gemcitabine plus nab-paclitaxel until progression or given sequentially with 5-fluorouracile plus irinotecan (FOLFIRI.3) for first-line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC): a randomized phase II study (PRODIGE 37-FIRGEMAX)","volume":"36","author":"Taieb","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2018.06.009_bib0090","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.4117","article-title":"Nab-paclitaxel plus S-1\u00a0followed by S-1\u00a0maintenance therapy as a first-line strategy for advanced pancreatic adenocarcinoma","volume":"36","author":"Shi","year":"2018","journal-title":"J Clin Oncol"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455118301966?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455118301966?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,21]],"date-time":"2018-09-21T08:44:27Z","timestamp":1537519467000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455118301966"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":18,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["S0007455118301966"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2018.06.009","relation":{},"ISSN":["0007-4551"],"issn-type":[{"type":"print","value":"0007-4551"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Strat\u00e9gies de maintenance dans les cancers du pancr\u00e9as avanc\u00e9s\u00a0: rationnel et enjeux","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2018.06.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}